State-run Oil India's profit drops as fuel prices tank
Increased fuel demand in two out of three months of the quarter, led by gasoline and aviation fuel, could not offset the sharp fall in oil prices.
The company's crude oil price realization, or price at which it sells, dropped 22% compared to the previous year, reaching $66.20 per barrel.
Global Brent crude oil prices, a key raw material for refiners, dropped 9.5% in the April-June quarter, following a 1.2% decline last year.
That led revenues from the crude oil segment, which forms two-thirds of the topline, to drop 21%, with overall revenue falling 14%.
Oil India's standalone net profit, which excludes earnings from its joint ventures and overseas operations, decreased 45% to 8.13 billion rupees ($92.8 million) in the quarter ended June 30.
Analysts, on average, had estimated a profit of 13.2 billion rupees, as per data compiled by LSEG.
Rival Oil and Natural Gas Corp (ONGC.NS), opens new tab is scheduled to report later in the day.
($1 = 87.6310 Indian rupees)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
5 minutes ago
- Reuters
Olam Group's first-half profit soars on higher food ingredients prices
Aug 14 (Reuters) - Singapore's Olam Group ( opens new tab reported a near seven-fold jump in first-half earnings on Thursday, primarily driven by strong performance at its food ingredients division due to higher average sales price. Olam, one of the world's biggest agricultural commodity traders, has been ramping up efforts to unlock value through a stake sale in Olam Agri to Saudi Arabia's agricultural and livestock investment firm, SALIC. It is also looking to demerge and list its food ingredients business, Ofi. "Pursuant to the proposed sale of Olam Agri to SALIC and the plan to responsibly divest the assets and businesses of the remaining Olam Group, our focus is to prioritise Ofi and support its efforts in realising its full potential value," said CEO Sunny Verghese. Ofi, a diversified food and beverage platform, reported revenue of S$14.7 billion ($11.49 billion) in the six months to June 30, around 52% higher than last year, with operating earnings jumping 13% to S$535.8 million. That boosted the group's reported profit attributable to S$323.8 million for the first half of 2025, compared with S$48 million a year earlier. It declared an interim dividend of 2 Singapore cents per share. ($1 = 1.2795 Singapore dollars)
Reuters
35 minutes ago
- Reuters
CK Hutchison ports deal in focus as Hong Kong conglomerate reports results
HONG KONG, Aug 14 (Reuters) - Investors will look for comments from CK Hutchison ( opens new tab on the status of its ports business sale to a consortium led by U.S. investment firm BlackRock (BLK.N), opens new tab when the Hong Kong conglomerate reports its interim results on Thursday. The ports-to-telecoms group will present its results at 5 p.m. (0900 GMT), offering analysts the first opportunity to quiz the management about the plan to sell the ports business since it was announced in March. Departing from its usual practice, CK Hutchison did not brief analysts or media about its 2024 earnings, released after it made public its plan to sell the business, which includes two ports along the strategic Panama Canal. Since the plan to sell 43 ports in 23 countries to a group led by BlackRock (BLK.N), opens new tab and Italian billionaire Gianluigi Aponte's family-run shipping firm MSC was announced, CK Hutchison has faced a firestorm of criticism from China. In the latest announcement on July 28, the conglomerate said it was in talks with the consortium pursuing its $22.8 billion ports business to add a Chinese "major strategic investor" to the bid, after their exclusive talks ended. It said changes would be necessary to secure regulatory approval in relevant jurisdictions and that it would allow as much time as needed to achieve that. Sources have told Reuters the investor was COSCO ( opens new tab - one of the world's dominant, vertically integrated marine transportation firms. They said COSCO was seeking a bigger stake while the other parties in the consortium were keen to keep it a minority. While any stake by COSCO is not yet clear, an inclusion of a Chinese investor would alleviate China's national security concerns and have its blessing, the sources and other experts have said. U.S. President Donald Trump had earlier called for the removal of Chinese ownership in the Panama Canal, which now accounts for more than 40% of U.S. container traffic valued at $270 billion annually. Ahead of the results, UBS forecast a 6% rise in underlying profit for the first six months, as ports and retail business growth and a weakening dollar offset the negative impact of oil prices. However, one-off losses, including from the completion of the 3UK merger, could weigh on the conglomerate's net profit. Morgan Stanley rated CK Hutchison "overweight" last month, citing potential strategic transactions, attractive valuation, and strong balance sheet.
Reuters
35 minutes ago
- Reuters
Focus: China pharma firms turn to local reagent suppliers to cut costs and delivery times
SHANGHAI, Aug 14 (Reuters) - Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as reagents from local manufacturers, industry executives and managers said, as they seek to cut costs and delivery times. Western reagent suppliers including U.S.-based Thermo Fisher Scientific and Germany's Merck ( opens new tab have profited in the world's second-largest pharmaceutical market from the compounds used in lab tests for analysis and quality control. But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are spurring Chinese companies to request products from local rivals like Shanghai Titan Scientific ( opens new tab and Nanjing Vazyme Biotech ( opens new tab instead, the executives and managers said. The five who spoke to Reuters work at Chinese firms involved in the purchase or supply of reagents and their comments are an early sign of an expected industry shift toward more Chinese purchases. China's reagent market for lab and diagnostic use has been to some extent supplied by imports, which were valued at $5.76 billion in 2024, down slightly from $5.83 billion in 2023, according to U.N. Comtrade data. "It is actually more advantageous (for reagents to be local) because the timeliness requirement is high," said Ma Xingquan, co-president of pharmaceutical research firm ChemPartner PharmaTech ( opens new tab. Most reagents it uses in its pre-clinical work are products that are made in China by firms including Titan and Shanghai Aladdin Biochemical Technology ( opens new tab, he said. ChemPartner's usage of locally made reagents would probably increase further as new products become available, Ma added. The rush to use domestically made reagents has accelerated since April, the month China raised duties on U.S. goods to 125%, a manager at Titan and an executive at Vazyme said, though the levies have since been lowered as Beijing and Washington continue trade talks. Some Chinese drugmakers were worried about tariff policy uncertainty, Titan product manager Yang Dong said. Since April, more than 90% of Vazyme's customers have discussed replacing imported reagents with its products, Vazyme Senior Vice President Xu Xiaoyu said. "Before April, customers were only saying long term, they hope to be able to replace (reagents) with those locally made, it would be better," Xu said. "But to customers these tariffs are like a shock in a short period of time. They clearly felt this type of direct impact... their impetus (for replacement) will be stronger." Titan and Vazyme are both forecast to report strong sales growth this year, according to brokers. China International Capital Corp expects Titan's annual revenue to grow 22% to 3.52 billion yuan ($490.39 million) this year, while Vazyme's revenue is set to rise 15% to 1.59 billion yuan over the same period, according to Soochow Securities. "There is still a lot of room for substitution of imported biological reagent enzymes, clients are strongly interested in locally-made replacements," Soochow said in a recent note. Shares in Titan and Vazyme have risen about 54% and 18% respectively since the start of the year. Merck and Thermo Fisher shares have fallen about 21% and 8% respectively over the same period. Morningstar analyst Max Jousma expects China's reagents market to grow more than 10% annually over the next five years, driven by government support for the biotech and pharmaceutical sectors and growth in research and development activity and in-vitro diagnostic testing. Merck and Swiss diagnostics group Roche Holding (ROG.S), opens new tab are moving some of their reagent production closer to their Chinese customers. In 2023, Merck announced plans to invest 70 million euros ($81.35 million) in a reagents facility in Nantong that is on track to begin operations next year. Merck declined to comment on any short-term shifts in ordering patterns from Chinese customers. "The decision to invest in reagent manufacturing in Nantong reflects our commitment to supporting the growing needs of life science and biopharma customers in China and the broader Asia-Pacific region," it said in a statement. Roche is expanding production, laboratory and logistics facilities from 2028 in Suzhou, where it produces reagents for diagnostic systems, the company said in a statement. The expansion will help it meet increasing demand for diagnostic solutions in China and parts of Asia-Pacific, it said. Thermo Fisher declined to comment on its reagent sales and strategy to compete against local manufacturers in China, citing a policy of not providing details of its business by product line or country. Chinese drugmakers that use reagents from Western companies and are looking to purchase substitutes from local firms will face some challenges given the products are difficult to switch during or after the regulatory approval process because of a need for material consistency, industry experts said. "Switching reagents will cause significant disruption and delay for drug development," said Huang Linfeng, a scientist specialising in RNA biology at Duke Kunshan University. Another hurdle is manufacturer access to technology or processes, some of which could still be protected under patent or not disclosed, said Cheng Shaojun, a vice-general manager at supplier Fu Chen (Tianjin) Chemical Reagents Co. "(Reagent) production equipment is also not necessarily able to be bought," he added. ($1 = 0.8605 euros) ($1 = 7.1779 Chinese yuan renminbi)
